SCHEMBL22346860

SCHEMBL22346860

Cc1cc(Nc2nc(N3CCC[C@H](NC(=O)C4CCN(C5CNC5)CC4)C3)cnc2C(N)=O)sn1

nearest known ligand 0.70

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 17/20 0.70
▸ JAK3 P52333 15/20 0.70
▸ LCK P06239 11/20 0.70
▸ EGFR P00533 7/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22359050 1.00 BTK (0.70) BTKJAK3LCKEGFR
SCHEMBL24411708 1.00 BTK (0.70) BTKJAK3LCKEGFR
SCHEMBL22358883 0.91 BTK (0.76) BTKJAK3LCKEGFR
SCHEMBL22359046 0.90 BTK (0.74) BTKJAK3LCKEGFR
SCHEMBL22346173 0.90 BTK (0.74) BTKJAK3LCKEGFR
SCHEMBL18283758 0.90 BTK (0.78) BTKJAK3LCKEGFR
SCHEMBL20540516 0.90 BTK (0.78) BTKJAK3LCKEGFR
SCHEMBL24411778 0.89 BTK (0.55) BTKJAK3LCKEGFR
SCHEMBL22346050 0.85 BTK (0.84) BTKJAK3LCKEGFR
SCHEMBL22346051 0.85 BTK (0.84) BTKJAK3LCKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3924350-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY Nurix Therapeutics, Inc. (US) 2021-12-22 — — EP disclosed
WO-2020167518-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2020-08-20 — — WO disclosed
Send feedback